Immunic, Inc. is trading 6.7% up at $12.49 as shares appear to be rebounding following recent biotech and small-cap pressure.
- There are no fresh company-specific headlines, earnings reports, or clinical trial readouts emerging on June 11, 2026, to explain the move.
- The advance follows several volatile sessions this week, with the stock gaining ground alongside a modestly higher broader market.
- No single identified catalyst is driving today's price action after recent sector-wide weakness.